Table 3.
Clinical outcomes and laboratory measurements of study patients grouped according to COVID-19 PR:HR slope
| Entire cohort (N = 75) | COVID-19 PR:HR slope behavior |
P value | ||
|---|---|---|---|---|
| Negative PR:HR slope (n = 38) | Positive PR:HR slope (n = 37) | |||
| Clinical endpoints | ||||
| Death | 14 (18.7) | 3 (7.9) | 11 (29.7) | .019∗ |
| Endotracheal intubation | 24 (32.0) | 8 (21.1) | 16 (43.2) | .050∗ |
| Mean length of hospital stay (days) | 11.7 ± 0.7 | 11.0 ± 0.9 | 12.4 ± 1.10 | .31 |
| Patients needing ICU stay (n) | 42 (56) | 17 (18.4) | 25 (67.6) | .06 |
| Laboratory values | ||||
| Peak hs-troponin T (ng/L) | 159.8 ± 46.4 | 64.1 ± 17.6 | 243.5 ± 83.5 | .053∗ |
| Peak C-reactive protein (μg/mL) | 21.2 ± 1.6) | 19.2 ± 2.2 | 23.2 ± 2.5 | .22 |
| Peak d-dimer (ng/mL) | 4899.7 ± 1347.3 | 3411.7 ± 1570.6 | 6387.8 ± 2184.4 | .27 |
| Peak ferritin (ng/mL) | 2158.5 ± 476.2 | 1912.9 ± 435.1 | 2356.4 ± 790.0 | .65 |
| Peak creatine phosphokinase (U/L) | 762.1 ± 194.5 | 614.0 ± 233.5 | 918.3 ± 316.1 | .44 |
| Peak pro-calcitonin (ng/mL) | 10.00 ± 6.0 | 13.13 ± 10.8 | 6.41 ± 3.7 | .58 |
| Peak pro-BNP (ng/L) | 4031.9 ± 1407.1 | 3778.4 ± 1957.8 | 4299.5 ± 2079.9 | .86 |
| Peak INR | 1.31 ± 0.0 | 1.232 ± 0.0 | 1.380 ± 0.0 | <.001∗ |
| Peak fibrinogen (mg/dL) | 698.9 ± 34.3 | 758.6 ± 45.7 | 654.5 ± 48.3 | .14 |
| Peak IL-6 (pg/mL) | 408.4 ± 206.9 | 908.8 ± 627.1 | 173.0 ± 51.7 | .10 |
Values are given as n (%) or mean ± SEM unless otherwise indicated.
BNP = B-type natriuretic peptide; COVID-19 = coronavirus 2019; HR = heart rate; hs-troponin = high-sensitivity troponin; ICU = intensive care unit; IL-6 = interleukin 6; INR = international normalized ratio.
∗
Statistically significant.